{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:16:09Z","timestamp":1777378569364,"version":"3.51.4"},"reference-count":75,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anaesth Intensive Care"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:p>The clinical utility of most analgesic drugs is altered in the presence of patients with impaired renal or hepatic function not simply because of altered clearance of the parent drug, but also through production and accumulation of toxic or therapeutically active metabolites. Some analgesic agents may also aggravate pre-existing renal and hepatic disease.<\/jats:p>\n                  <jats:p>A search was performed, taking in published articles and pharmaceutical data to determine available evidence for managing acute pain effectively and safely in these two patient groups. The resulting information consisted mainly of small group pharmacokinetic studies or case reports, which included a large variation in degree of organ dysfunction.<\/jats:p>\n                  <jats:p>In the presence of renal impairment, those drugs which exhibit the safest pharmacological profile are alfentanil, buprenorphine, fentanyl, ketamine, paracetamol (except with compound analgesics), remifentanil and sufentanil: none of these deliver a high active metabolite load, or suffer from significantly prolonged clearance. Amitriptyline, bupivacaine, clonidine, gabapentin, hydromorphone, levobupivacaine, lignocaine, methadone, mexiletine, morphine, oxycodone and tramadol have been used in the presence of renal failure, but do require specific precautions, usually dose reduction. Aspirin, dextropropoxyphene, non-steroidal anti-inflammatory drugs and pethidine, should not be used in the presence of chronic renal failure due to the risk of significant toxicity.<\/jats:p>\n                  <jats:p>In the presence of hepatic impairment, most drugs are subject to significantly impaired clearance and increased oral bioavailability, but are poorly studied in the clinical setting. The agent least subject to alteration in this context is remifentanil; however the drugs\u2019 potency has other inherent dangers. Other agents must only be used with caution and close patient monitoring. Amitriptyline, carbamazepine and valproate should be avoided as the risk of fulminant hepatic failure is higher in this population, and methadone is contraindicated in the presence of severe liver disease.<\/jats:p>","DOI":"10.1177\/0310057x0503300306","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T04:05:54Z","timestamp":1547611554000},"page":"311-322","source":"Crossref","is-referenced-by-count":137,"title":["Acute Pain Management Pharmacology for the Patient with Concurrent Renal or Hepatic Disease"],"prefix":"10.1177","volume":"33","author":[{"given":"E. J.","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Anaesthesia, Royal Adelaide Hospital, Adelaide, South Australia"},{"name":"Consultant Anaesthetist, Department of Anaesthesia, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,6,1]]},"reference":[{"key":"bibr1-0310057X0503300306","volume-title":"Implementation and Evaluation of Clinical Practice Guidelines.","author":"A Guide to the Development,","year":"1999"},{"key":"bibr2-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199631060-00002"},{"key":"bibr3-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1991.tb09852.x"},{"key":"bibr4-0310057X0503300306","first-page":"303","volume":"6","author":"Park G.R.","year":"1989","journal-title":"Eur J Anaesthesiol"},{"key":"bibr5-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198701000-00009"},{"key":"bibr6-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198905000-00006"},{"key":"bibr7-0310057X0503300306","volume":"27","author":"Codeine phosphate (Fawns and McAllen) product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW,"},{"key":"bibr8-0310057X0503300306","volume":"27","author":"Digesic product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr9-0310057X0503300306","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/j.1875-9114.1997.tb03750.x","volume":"17","author":"Koehntop D.E.","year":"1997","journal-title":"Pharmacotherapy"},{"key":"bibr10-0310057X0503300306","first-page":"371","volume":"46","author":"Koren G.","year":"1984","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"bibr11-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(94)00121-Z"},{"key":"bibr12-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1191\/026921601669626431"},{"key":"bibr13-0310057X0503300306","volume":"27","author":"Dilaudid product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr14-0310057X0503300306","volume-title":"Australian Medicines Handbook.","author":"Opioid Analgesics.","year":"2003"},{"key":"bibr15-0310057X0503300306","first-page":"20","volume":"27","author":"Methadone Syrup product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr16-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/62.1.28"},{"key":"bibr17-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199407000-00013"},{"key":"bibr18-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(97)00076-6"},{"key":"bibr19-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200210000-00011"},{"key":"bibr20-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.4.903"},{"key":"bibr21-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200005000-00038"},{"key":"bibr22-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199707000-00006"},{"key":"bibr23-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/70.5.511"},{"key":"bibr24-0310057X0503300306","first-page":"S44","volume":"67","author":"Kaiko R.F.","year":"1991","journal-title":"Postgrad Med J"},{"key":"bibr25-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1016\/0952-8180(95)00092-5"},{"key":"bibr26-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/71.5.738"},{"key":"bibr27-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.137.1.84"},{"key":"bibr28-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199709000-00012"},{"key":"bibr29-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1007\/BF03013962"},{"key":"bibr30-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/81.2.265"},{"key":"bibr31-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/81.6.881"},{"key":"bibr32-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198803000-00010"},{"key":"bibr33-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198901000-00001"},{"key":"bibr34-0310057X0503300306","volume":"27","author":"Tramal product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr35-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200203000-00026"},{"key":"bibr36-0310057X0503300306","first-page":"37","volume":"39","author":"Lowenthal D.T.","year":"1993","journal-title":"Clin Nephrol"},{"key":"bibr37-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.1999.00659.x"},{"key":"bibr38-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.44"},{"key":"bibr39-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1007\/BF00630290"},{"key":"bibr40-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199501000-00014"},{"key":"bibr41-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/64.4.436"},{"key":"bibr42-0310057X0503300306","volume-title":"in Australian Medicines Handbook.","author":"Local Anaesthetics.","year":"2003"},{"key":"bibr43-0310057X0503300306","first-page":"83","author":"Lidocaine.","year":"1994","journal-title":"American Association for Clinical Chemistry, Inc, Washington, DC"},{"key":"bibr44-0310057X0503300306","volume":"27","author":"Lignocaine Hydrochloride Injection (CSL) product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr45-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200207000-00039"},{"key":"bibr46-0310057X0503300306","volume":"27","author":"Naropin product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr47-0310057X0503300306","volume":"27","author":"Chirocaine product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr48-0310057X0503300306","volume-title":"Australian Medicines Handbook.","author":"Drugs affecting heart rhythm.","year":"2003"},{"key":"bibr49-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a061402"},{"key":"bibr50-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.105"},{"key":"bibr51-0310057X0503300306","first-page":"25","author":"Akers J.","year":"2000","journal-title":"Australian and New Zealand College of Anaesthetists, Melbourne, Victoria"},{"key":"bibr52-0310057X0503300306","volume-title":"Australian Medicines Handbook.","author":"Intravenous General Anaesthetics.","year":"2003"},{"key":"bibr53-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190213"},{"key":"bibr54-0310057X0503300306","volume-title":"Australian Medicines Handbook.","author":"Antiepileptics.","year":"2003"},{"key":"bibr55-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00814.x"},{"key":"bibr56-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.3.315"},{"key":"bibr57-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.2.446"},{"key":"bibr58-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1159\/000187784"},{"key":"bibr59-0310057X0503300306","first-page":"S74","volume":"32","author":"Wyllie E.","year":"1991","journal-title":"Epilepsia"},{"key":"bibr60-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(99)00936-7"},{"key":"bibr61-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259935"},{"key":"bibr62-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1136\/adc.87.6.462"},{"key":"bibr63-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90748-6"},{"key":"bibr64-0310057X0503300306","volume":"27","author":"Epilim product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr65-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb05020.x"},{"key":"bibr66-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01514-5"},{"key":"bibr67-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753010-00012"},{"key":"bibr68-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199812050-00005"},{"key":"bibr69-0310057X0503300306","volume":"27","author":"Celebrex product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr70-0310057X0503300306","volume":"27","author":"Dynastat product monograph.","year":"2003","journal-title":"MediMedia Australia, St Leonards, NSW"},{"key":"bibr71-0310057X0503300306","volume-title":"In MIMS Annual.","volume":"27","author":"Vioxx product monograph.","year":"2003"},{"key":"bibr72-0310057X0503300306","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00043.x"},{"key":"bibr73-0310057X0503300306","first-page":"255","volume":"34","author":"Berg K.J.","year":"1990","journal-title":"Clin Nephrol"},{"key":"bibr74-0310057X0503300306","volume-title":"Australian Medicines Handbook.","author":"Non-opioid Analgesics.","year":"2003"},{"key":"bibr75-0310057X0503300306","first-page":"33","author":"Acetaminophen.","year":"1994","journal-title":"American Association for Clinical Chemistry, Inc, Washington, DC"}],"container-title":["Anaesthesia and Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0310057X0503300306","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0310057X0503300306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:11:34Z","timestamp":1777367494000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0310057X0503300306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1177\/0310057X0503300306"],"URL":"https:\/\/doi.org\/10.1177\/0310057x0503300306","relation":{},"ISSN":["0310-057X","1448-0271"],"issn-type":[{"value":"0310-057X","type":"print"},{"value":"1448-0271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}